profit from every $100 of sales.
$0$100
Apimeds Pharmaceuticals US
$2.70-0.18% today
-87.9% in 1 year
1-year low $1.601-year high $39.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Apimeds Pharmaceuticals US sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$6.00 million of profit last year.
SalesProfit
Apimeds Pharmaceuticals US vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Apimeds Pharmaceuticals US | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Apimeds Pharmaceuticals US's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -1 | -1 | -1 | -12 | |
| -1 | -1 | -1 | -6 | |
| -1 | -1 | -1 | -6 | |
| -0.06 | -0.07 | -0.12 | -0.55 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 164 |
| Cash | 0 | 0 | 0 | 2 |
| Total debt | 1 | 0 | 1 | 8 |
| Total liabilities | 1 | 0 | 1 | 11 |
| -1 | 0 | -1 | 153 | |
| 12 | 12 | 12 | 11 | |
| – | -195.6% | – | -2.8% | |
| 93.7% | -2,440.3% | 102.3% | -3.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -0 | -1 | -1 | -9 | |
| – | – | – | 0 | |
| -0 | -1 | -1 | -9 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | 3 |
Valuation
- –
- –
- –
- 0.1×
- –
- –
- –
- -220.5%
- -147.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -2.9%
- -101.7%
- -0.0%
- -0.0%
- -0.0%
- –
Growth
- –
- –
- −1,124.6%
- –
- −2.0%
Financial health
- -1.1×
- 0.05
- 4.7%
- -20.2×
- 1.31
- 1.31
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 948
Bottom 21%of 871
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | -0.08 | – | – |
| Nov 12, 2025 | -0.14 | – | – |
| Aug 19, 2025 | -0.26 | – | – |
| May 19, 2025 | -0.05 | – | – |
| Dec 31, 2024 | -0.02 | – | – |
| Sep 30, 2024 | -0.03 | – | – |
| Jun 30, 2024 | -0.04 | – | – |
| Mar 31, 2024 | -0.02 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
64Pass
Philip Fisher
43No pass
Peter Lynch
59No pass
Joel Greenblatt
0No pass
Charlie Munger
36No pass
Terry Smith
41No pass
Questions about Apimeds Pharmaceuticals US
Is Apimeds Pharmaceuticals US a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Apimeds Pharmaceuticals US AI analysis
What does Apimeds Pharmaceuticals US do?
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc. It is in Drug Manufacturers - Specialty & Generic.
Does Apimeds Pharmaceuticals US pay a dividend?
No. Apimeds Pharmaceuticals US does not pay a dividend at the moment.
Is Apimeds Pharmaceuticals US stock halal?
No. Apimeds Pharmaceuticals US does not pass our halal screen: its debt is 191% of its market value, at or above the 33% limit. How we check
How has Apimeds Pharmaceuticals US stock done over the past year?
Down 87.9% over the past twelve months, to $2.70. It traded between $1.60 and $39.00 and is 93.1% below its high.
Who are Apimeds Pharmaceuticals US's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Apimeds Pharmaceuticals US's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.